Compare EOG Resources Inc (EOG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Merck & Co., Inc. — how do they compare? EOG Resources Inc trades at $138.75 (market cap $73.22B), while Merck & Co., Inc. trades at $127.89 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 4.2× EOG Resources Inc's market cap, and EOG Resources Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| EOG | MRK | |
|---|---|---|
Market Cap | $73.22B | $305.29B |
Sector | Energy | Health |
52-Week High | $149.89 | $129.52 |
52-Week Low | $101.78 | $77.60 |
Enterprise Value | $77.68B | $348.71B |
Dividend Yield | 2.97% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $138.01, down 1.15% on the day, with a bullish technical signal from moving averages and strong analyst support. The company maintains robust profitability with a net income margin of 23.39% and has beaten earnings estimates for the last three quarters. Recent news highlights its valuation discount and operational strength, with a consensus price target of $156.40 suggesting upside potential.
The outlook for EOG is positive, driven by consistent earnings beats, solid cash flow, and a favorable analyst consensus. Key risks include oil price volatility and elevated capital expenditures. The stock presents an opportunity for growth investors seeking exposure to a high-quality energy producer trading below target prices.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
